SLC7A11 and melanoma: The cysteine cycle has recently been identified as a potential target for melanoma therapy, as inhibiting the function of xCT with (S)-4-carboxyphenylglycine has demonstrated melanoma cell cytotoxicity, especially in combination with inhibition of GSH synthesis using buthionine sulfoximine [52].